Fierce Pharma
MAY 22, 2024
Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. | Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer.
Clarivate
MAY 22, 2024
The Journal Citation Reports 2024 release will include unified rankings across subject categories, helping to simplify journal performance assessment. At Clarivate , we are deeply committed to working with the research community to safeguard research integrity. We invest significant effort in ensuring that the Web of Science Core Collection only contains content from trustworthy sources and over the last few years, we’ve introduced a series of editorial policy changes that affect the Journal Cit
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 22, 2024
Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.
MedCity News
MAY 22, 2024
During a fireside chat at MedCity News’ INVEST conference, Nitin Natarajan — deputy director at the Cybersecurity and Infrastructure Security Agency (CISA) — shared some key ideas that people need to understand about the current state of cybersecurity in the healthcare industry. For instance, he reminded us that things won’t get better overnight, and that cybersecurity requires an all-hands-on deck approach.
Fierce Pharma
MAY 22, 2024
The more than 53,000 women in the U.S. | The more than 53,000 women in the U.S. who have filed injury lawsuits against Johnson & Johnson have added ammunition for their claims as new research indicates there is an association between long-term use of talcum-based powders and an increased risk of developing ovarian cancer.
pharmaphorum
MAY 22, 2024
GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
MAY 22, 2024
A think tank set up by former UK Prime Minister Tony Blair has called for the formation of a public-private trust that could oversee the sharing of anonymised patient data with trusted researchers.
Fierce Pharma
MAY 22, 2024
When it comes to supporting cancer care and other therapeutic approaches in low- and middle-income countries (LMICs), Bristol Myers Squibb is taking a long-term view. | In its quest to reach more than 200,000 patients with its medicines in low- and middle-income countries by 2033, BMS is embarking on a 10-year access effort.
PharmaTech
MAY 22, 2024
The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.
Fierce Pharma
MAY 22, 2024
Merck KGaA’s North American life science division, MilliporeSigma, has made U.S. | The U.S. Department of Justice on Wednesday announced that Florida residents Pen Yu, 51, and Gregory Muñoz, 45, each pleaded guilty to one count of wire fraud conspiracy for their roles in a scheme to “fraudulently procure deeply discounted products” from Merck KGaA's MilliporeSigma and export them to China using faked export documents.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
MAY 22, 2024
There have been several advancements in the women’s health space, but we still have a long way to go, execs said during a recent panel. The post What Frustrates 3 Women’s Health Execs appeared first on MedCity News.
Fierce Pharma
MAY 22, 2024
Hawaii has ordered BMS and Sanofi to pay a $916M for failing to warn about the potential ineffectiveness of blood thinner Plavix in some patients.
Pharmaceutical Technology
MAY 22, 2024
As the nitrosamine scandal continues, we explore the advancements in parenteral packaging materials that are reducing the risk of this contaminant in modern injectables.
pharmaphorum
MAY 22, 2024
Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible.
MedCity News
MAY 22, 2024
To win the battle against rare diseases, drug developers must work hand-in-hand with patients. The post Allying With Patients to Make Every Cure Possible appeared first on MedCity News.
pharmaphorum
MAY 22, 2024
Digital health firm Click Therapeutics has bought the assets of Better Therapeutics to speed up development of a prescription digital therapeutic for obesity
European Pharmaceutical Review
MAY 22, 2024
The European Commission (EC) has approved the first and only biosimilar versions of the reference medicines Xgeva ® and Prolia ® in Europe. Sandoz shared that Wyost ® (denosumab) is approved for treating cancer-related bone disease. Jubbonti ® (denosumab) is authorised as an osteoporosis treatment. The decision by the EC “is a major step in advancing the Sandoz growth strategy”, the company asserted.
pharmaphorum
MAY 22, 2024
Immune checkpoint enhancer biotech AltruBio raises $225m to support phase 2 trials of its PSGL-1-targeted drug for ulcerative colitis
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
MAY 22, 2024
Biogen’s acquisition of Human Immunology Biosciences brings a drug candidate with potential applications in multiple immune-mediated disorders. The deal comes just prior to the scheduled presentation of clinical data in two of them. The post Biogen Immunology Strategy Comes Into Focus With $1B HI-Bio Acquisition appeared first on MedCity News.
PharmaTimes
MAY 22, 2024
The nanocage technology combines both mRNA and traditional virus-based vaccines to create virus-like efficacious vaccines
European Pharmaceutical Review
MAY 22, 2024
A total of 33 regulatory authorities have been granted designation as World Health Organization ( WHO ) Listed Authorities under the WLA framework. The agencies holding this status have been approved and validated as compliant and committed to upholding the “highest level of regulatory standards and practices for quality, safety and efficacy of medicines and vaccines ”.
PharmaTimes
MAY 22, 2024
Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Healthcare Success
MAY 22, 2024
Is your email marketing HIPAA compliant? Do you have adequate encryption at every step? Are you sure? Remember, even a patient’s email address could be considered PHI if linked to a health condition or treatment. If you are suddenly feeling a little uneasy, I promise you are not alone. Most healthcare marketers are unaware that seemingly innocuous patient email marketing campaigns are yet another area where you could inadvertently run afoul with HIPAA regulations, or, even worse, suffer a breach
pharmaphorum
MAY 22, 2024
An attempt by Ultragenyx to have a lawsuit filed by the family of Henrietta Lacks dismissed before it could be heard has failed. US District Judge Deborah Boardman turned down Ultragenyx’s request in a Baltimore federal court, concluding that the allegation that the company had profited from cells harvested from Lacks without her consent should be held up to scrutiny.
PharmaVoice
MAY 22, 2024
Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.
Pharmaceutical Commerce
MAY 22, 2024
The latest news for pharma industry insiders.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Copyright Clearance Center
MAY 22, 2024
The post Mission Critical: Society Publishing in an Open Access World appeared first on Copyright Clearance Center.
PharmaVoice
MAY 22, 2024
Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.
PharmaTech
MAY 22, 2024
EBPT provides expert support for Environmental Monitoring programs, ensuring clean and controlled manufacturing environments. Our services include designing monitoring programs, collecting samples, and analyzing data using advanced equipment. With locations across the U.S., EBPT offers nationwide support to pharmaceutical and medical device clients with standardized practices and specialized expertise.
PharmExec
MAY 22, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Sciences discusses new skills that members of generation Alpha will bring to the pharma industry and potential struggles that they may face.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
304 
Let's personalize your content